Please wait while we retrieve your external webpage

Roche’s Tecentriq Wins Speedy U.S. FDA Review For Small Cell Lung Cancer

One thought on “Roche’s Tecentriq Wins Speedy U.S. FDA Review For Small Cell Lung Cancer

  1. This will be an important development for thoracic oncology. The results of the IMpower133 trial, which demonstrated a significant survival benefit with the addition of atezolizumab to standard carbo/etoposide chemo as first line treatment for extensive stage small cell lung cancer (SCLC), were not astonishingly better than chemo, but they are enough that they should change the standard of care. Significant improvements in overall survival, even if not overwhelming, are infrequent enough in oncology in general and SCLC specifically, that we should be eager to adopt them when available. Having this regimen approved will make it far easier to pursue this combination broadly as a new standard of care.

Leave a Reply